Role of β-lactamase inhibitors in enterobacterial isolates producing extended-spectrum β-lactamases

Journal of Antimicrobial Chemotherapy

Volumn 61, Issue 2, 2008, Pages 309-314

  Bhattacharjee, Amitabha ^a   Sen, Malay Ranjan ^a   Prakash, Pradyot ^a   Anupurba, Shampa ^a  

^a BANARAS HINDU UNIVERSITY   (India)

Author keywords

Aztreonam; ESBLs; OXA 10

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; AZTREONAM; BETA LACTAMASE AMPC; BETA LACTAMASE INHIBITOR; CEFEPIME; CEFOTAXIME; CEFOXITIN; CEFPODOXIME; CEFTAZIDIME; CEFTRIAXONE; CEFTRIAXONE PLUS SULBACTAM; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLAVULANIC ACID; EXTENDED SPECTRUM BETA LACTAMASE; GENTAMICIN; IMIPENEM; MONOBACTAM DERIVATIVE; NETILMICIN; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; SULBACTAM; SULPERAZON; SULTAMICILLIN; TIMENTIN; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; ENTEROBACTER INFECTION; ENTEROBACTERIACEAE; ENZYME SYNTHESIS; ESCHERICHIA COLI; HUMAN; IN VITRO STUDY; INDIA; KLEBSIELLA OXYTOCA; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; NONHUMAN; PROTEUS MIRABILIS; SCREENING TEST; STANDARDIZATION; STRAIN DIFFERENCE; UNIVERSITY HOSPITAL;

BETA-LACTAMASES; DRUG RESISTANCE, BACTERIAL; ENTEROBACTERIACEAE; ENZYME INHIBITORS; HUMANS; MICROBIAL SENSITIVITY TESTS;

EID: 38349098486     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkm494     Document Type: Article

References (15)

1. Bradford PA. Extended-spectrum β-lactamases in the 21st century: characterization, epidemiology and detection of this resistance threat. Clin Microbiol Rev 2001; 14: 933-51.
2. Paterson DL. Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum β-lactamases (ESBLs). Clin Microbiol Infect 2000; 6: 460-3.
3. Bradford PA, Urban C, Marino N et al. Imipenem resistance in Klebsiella pneumoniae is associated with the combination of ACT-1, a plasmid-mediated AmpC β-lactamase, and loss of an outer membrane protein. Antimicrob Agents Chemother 1997; 41: 563-9.
4. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Disc Susceptibility Testing: Fifteenth Informational Supplement M100-S15. CLSI, Wayne, PA, USA, 2005.
5. Deutsche Industrie Norm-Medizinsche Mikrobiologie. Methoden zur Empfindlichkeitsprufung von bakleriellen krankheitserregen gegen chemotherapeutika. 2000. Beiblatt 1 zu DIN 98940-4. Deutsches institut fur Normung a. V., Berlin, Germany.
6. British Society for Antimicrobial Chemotherapy. A guide to sensitivity testing. J Antimicrob Chemother 1991; 27: 1-50.
7. Bert F, Branger C, Zechovsky NL. Identification of PSE and OXA β-lactamase genes in Pseudomonas aeruginosa using PCR-restriction fragment length polymorphism. J Antimicrob Chemother 2002; 50 11-8.
8. XA-1 genes in Enterobacteriaceae. FEMS Microbiol Lett 2003; 223: 147-51.
9. Lee S, Park YJ, Kim M et al. Prevalence of Ambler class A and D β-lactamases among clinical isolates of Pseudomonas aeruginosa in Korea. J Antimicrob Chemother 2005; 56: 122-7.
10. Belkum AV, Kluytmans J, Leeuwen WV et al. Multicenter evaluation of arbitrarily primed PGR for typing of Staphylococcus aureus strains. J Clin Microbiol 1995; 33: 1537-47.
11. Chmelnitsky I, Carmeli Y, Leavitt A et al. CTX-M-2 and a new CTX-M-39 enzyme are the major extended-spectrum β-lactamases in multiple Escherichia coli clones isolated in Tel Aviv, Israel. Antimicrob Agents Chemother 2005; 49: 4745-50.
12. Thomson KS, Weber DA, Sanders CC et al. β-Lactamase production in members of family Enterobacteriaceae and resistance to β-lactam-enzyme inhibitor combinations. Antimicrob Agents Chemother 1990; 34 622-7.
13. Thomson KS, Sanders CC, Moland ES. Use of microdilution panels with and without β-lactamase inhibitors as a phenotypic test for β-lactamase production among Escherichia coli, Klebsiella spp., Enterobacter spp., Citrobacter freundii, and Serratia marcescens. Antimicrob Agents Chemother 1999; 43: 1393-400.
14. Sturenburg E, Mack D. Extended-spectrum β-lactamases: Implications for the clinical microbiology laboratory, therapy, and infection control. J Infect 2003; 47: 273-99.
15. Luzzaro F, Mezzatesta M, Mugnaioli C et al. Trends in production of extended-spectrum β-lactamases among enterobacteria pf medical interest: Report of the second Italian nationwide survey. J Clin Microbiol 2006; 44: 1659-64.